EGLT Egalet Corporation

4.22
0  -4%
Previous Close 4.38
Open 4.41
Price To book 20.28
Market Cap 104.00M
Shares 24,645,000
Volume 176,037
Short Ratio 24.68
Av. Daily Volume 341,494

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

sNDA filed December 1, 2016.
OXAYDO
Acute and chronic moderate to severe pain
Phase 3 to be completed 4Q 2017. NDA planned for 2018.
Egalet-002
Moderate to severe chronic pain
Approved January 9, 2017.
Egalet-001 (ARYMO ER)
Abuse-Deterrent Morphine

Latest News

  1. Egalet Announces U.S. Food and Drug Administration Acceptance of File for Prior Approval Supplement for OXAYDO® (oxycodone HCl, USP) tablets C-II 10 mg and 15 mg Dosage Strengths
  2. Egalet Corporation Announces Changes to Board of Directors
  3. Egalet to Participate in Spring Investor Conferences
  4. Egalet Deploys Salesforce to Begin Educating Healthcare Providers about ARYMO™ ER
  5. The FDA News That Put The Wind Beneath Egalet Stock's Wings
  6. Egalet Can Tout Abuse-Deterrent Opioid Painkiller
  7. Egalet Corporation (Nasdaq: EGLT) to Ring The Nasdaq Stock Market Closing Bell
  8. Egalet Announces U.S. Food and Drug Administration Does Not Object to Egalet's Distribution of Materials and Communications to Healthcare Professionals Regarding Abuse-Deterrent Properties of ARYMO™ ER via Intranasal Route
  9. DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders it Has Filed a Complaint to Recover Losses Suffered by Investors in Egalet Corporation, Sets Lead Plaintiff Deadline of March 28, 2017 - EGLT
  10. DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Egalet Corporation (EGLT) & Lead Plaintiff Deadline - March 28, 2017
  11. IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Egalet Corporation and Encourages Investors with Losses to Contact the Firm
  12. EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Egalet Corporation - EGLT
  13. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Complaint to Recover Losses Suffered by Investors in Egalet Corporation
  14. Blog Coverage Egalet Receives New US and International Patents for Guardian(TM) Technology
  15. Egalet Gets 4 New Patents for Guardian Technology
  16. Egalet Announces Issuance of New U.S. and International Patents for Guardian™ Technology
  17. INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Egalet Corporation and Encourages Investors with Losses to Contact the Firm
  18. EGLT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Egalet Corporation and a Lead Plaintiff Deadline of March 28, 2017
  19. Pain Therapeutics’ Remoxy ER Secures FDA Regulatory Guidance (PTIE,EGLT)
  20. Nektar Pharma Opioid Drug Shows Promise In Phase 3